Given that CXCR4 acts as the receptor for SDF-1, a potent chemokine integral to tumor progression and growth,45 we employed AMD3100, a well-established CXCR4 antagonist widely used for HSPC mobilization from the bone marrow.49 The gene discussed is CXCR4; the disease is neoplasm.